Allison P. Drain

Allison P. Drain

Auto-generated profile, based on publicly available information

Allison P. Drain

Boston University, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2017 in Annual Review of Cancer Biology
Verified
Journal Article
Closed access
JLJennifer L Leight
Jennifer L Leight
ADAllison P. Drain
Allison P. Drain
VWValerie M Weaver
Valerie M Weaver
Solid tumors are characterized by a remodeled and stiffened extracellular matrix. The extracellular matrix is not a passive by-product of the tumor, but actively compromises tissue-specific differentiation, enhances tumor cell proliferation and survival, and fosters tumor cell invasion and migration. The tumor extracellular matrix also influences the behavior of the stromal cells, which through vicious, feedforward-reinforcing pathways promote tumor progression and compromise treatment efficacy. To investigate how the tumor extracellular matrix alters cancer phenotype and treatment, a number of three-dimensional, organotypic culture models have been developed that employ a variety of materials, including natural matrices, collagen, fibrin, and reconstituted basement membrane gels, as well as synthetic hydrogel materials such as polyacrylamide and polyethylene glycol. These models have been used to interrogate how specific microenvironmental features modify tumor and stromal cell function and to identify the molecular mechanisms that regulate tumorigenesis and therapeutic efficacy. To translate these findings into more effective treatment strategies for patients, clinically informed studies are needed that incorporate computational modeling and in vivo validation.

2 April 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ADAllison P. Drain
Allison P. Drain
NZNastaran Zahir
Nastaran Zahir
JNJason Northey
Jason Northey
HZHui Zhang
Hui Zhang
PHPo-Jui Huang
Po-Jui Huang
VWValerie M Weaver
Valerie M Weaver
Triple-negative breast cancers (TNBCs) are associated with poor survival mediated by treatment resistance. TNBCs are fibrotic, yet little is known regarding how the extracellular matrix (ECM) evolves following therapy and whether it impacts treatment response. Analysis revealed that while primary untreated TNBCs are surrounded by a rigid stromal microenvironment, chemotherapy-resistant residual tumors inhabit a softer niche. TNBC organoid cultures and xenograft studies showed that organoids interacting with soft ECM exhibit striking resistance to chemotherapy, ionizing radiation, and death receptor ligand TRAIL. A stiff ECM enhanced proapoptotic JNK activity to sensitize cells to treatment, whereas a soft ECM promoted treatment resistance by elevating NF-κB activity and compromising JNK activity. Treatment-resistant residual TNBCs residing within soft stroma had elevated activated NF-κB levels, and disengaging NF-κB activity sensitized tumors in a soft matrix to therapy. Thus, the biophysical properties of the ECM modify treatment response, and agents that modulate stiffness-dependent NF-κB or JNK activity could enhance therapeutic efficacy in patients with TNBC.

13 February 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
OMOri Maller
Ori Maller
ADAllison P. Drain
Allison P. Drain
ABAlexander S. Barrett
Alexander S. Barrett
SBSigne Borgquist
Signe Borgquist
BRBrian Ruffell
Brian Ruffell
VWValerie M Weaver
Valerie M Weaver
Collagen deposition and stromal stiffening accompany malignancy, compromise treatment, and promote tumor aggression. Clarifying the molecular nature of and the factors that regulate extracellular matrix stiffening in tumors should identify biomarkers to stratify patients for therapy and therapeutic interventions to improve outcome. We profiled lysyl hydroxylase- and lysyl oxidase-mediated collagen crosslinks and quantified the greatest abundance of total and complex collagen crosslinks in more aggressive human breast cancer subtypes with the stiffest stroma. These tissues also harbored the highest number of tumor-associated macrophages (TAM), whose therapeutic ablation not only reduced metastasis, but also concomitantly decreased accumulation of collagen crosslinks and stromal stiffening. Epithelial-targeted expression of the crosslinking enzyme lysyl oxidase had no impact on collagen crosslinking in PyMT mammary tumors, whereas stromal cell targeting did. Consistently, stromal cells in microdissected human tumors expressed the highest level of collagen crosslinking enzymes. Immunohistochemical analysis of a cohort of breast cancer patient biopsies revealed that stromal expression of lysyl hydroxylase two, an enzyme that induces hydroxylysine aldehyde-derived collagen crosslinks and stromal stiffening correlated significantly disease specific mortality. The findings link tissue inflammation, stromal cell-mediated collagen crosslinking and stiffening to tumor aggression and identify lysyl hydroxylase two as a novel stromal biomarker. Significance: We show infiltrating macrophages induce stromal fibroblast, and not epithelial, expression of collagen crosslinking enzymes that drive tumor stiffening. Stromal enzyme LH2 is significantly upregulated in breast cancer patients with the stiffest stroma, the most trivalent HLCCs and the worst prognosis, underscoring its potential as a biomarker and therapeutic target.

11 March 2021
Verified
Dataset
Closed access
CCChristopher Chen
Christopher Chen
ADAllison Drain
Allison Drain
There is an urgent need to better understand the cellular mechanisms driving liver fibrosis and to develop effective therapeutics. Hyaluronan is emerging as an important player in many fibrotic indications, and this is a very nice study investigating the role of hyaluronan in hepatic stellate cell (HSC) activation and liver fibrosis. The authors show that TGFb1 signaling through WT1 induces Has2 transcription in HSCs to increase production of hyaluronan in liver fibrosis. Using in vivo models of liver fibrosis and several in vivo and in vitro genetic manipulations, the authors convincingly demonstrate that increased HSC-derived hyaluronan from HAS2 binds CD44 on HSCs, which directly increases Notch1 transcription. They further show Notch1 is necessary for the profibrotic effect of HAS2. Finally, the authors demonstrate a potential for clinical translation of these findings by showing treatment with an inhibitor of hyaluronan synthesis reduces fibrosis in mouse models.

11 March 2021
Verified
Dataset
Closed access
CCChristopher Chen
Christopher Chen
ADAllison Drain
Allison Drain
BACKGROUND & AIMS: Angiocrine signaling by liver sinusoidal endothelial cells (LSECs) regulates hepatic functions such as growth, metabolic maturation, and regeneration. Recently, we identified GATA4 as the master regulator of LSEC specification during development. Herein, we studied the role of endothelial GATA4 in the adult liver and in hepatic pathogenesis. METHODS: We generated adult Clec4g-icretg/0xGata4fl/fl (Gata4LSEC-KO) mice with LSEC-specific depletion of Gata4. Livers were analyzed by histology, electron microscopy, immunohistochemistry/immunofluorescence, in situ hybridization, and LSECs were isolated for gene expression profiling, ChIP- and ATAC-sequencing. Partial hepatectomy was performed to assess regeneration. We used choline-deficient, l-amino acid-defined (CDAA) diet and chronic carbon tetrachloride exposure to model liver fibrosis. Human single cell RNA-seq data sets were analyzed for endothelial alterations in healthy and cirrhotic livers. RESULTS: Genetic Gata4 deficiency in LSECs of adult mice caused perisinusoidal liver fibrosis, hepatopathy and impaired liver regeneration. Sinusoidal capillarization and LSEC-to-continuous endothelial transdifferentiation were accompanied by a profibrotic angiocrine switch involving de novo endothelial expression of hepatic stellate cell-activating cytokine PDGFB. Increased chromatin accessibility and amplification by activated MYC mediated angiocrine Pdgfb expression. As observed in Gata4LSEC-KO livers, CDAA diet-induced perisinusoidal liver fibrosis was associated with GATA4 repression, MYC activation and a profibrotic angiocrine switch in LSECs. Comparison of CDAA-fed Gata4LSEC-KO and control mice demonstrated that endothelial GATA4 indeed protects against dietary-induced perisinusoidal liver fibrosis. In human cirrhotic livers, GATA4-positive LSECs and endothelial GATA4 target genes were reduced, while non-LSEC endothelial cells and MYC target genes including PDGFB were enriched. CONCLUSIONS: Endothelial GATA4 protects against perisinusoidal liver fibrosis by repressing MYC activation and profibrotic angiocrine signaling at the chromatin level. Therapies targeting the GATA4/MYC/PDGFB/PDGFRβ axis offer a promising strategy for prevention and treatment of liver fibrosis. LAY SUMMARY: The liver vasculature is supposed to play a major role in the development of liver fibrosis and cirrhosis, which can lead to liver failure and liver cancer. Herein, we discovered that structural and transcriptional changes induced by genetic deletion of the transcription factor GATA4 in the hepatic endothelium were sufficient to cause liver fibrosis. Activation of the transcription factor MYC and de novo expression of the "angiocrine" growth factor PDGFB were identified as downstream drivers of fibrosis and as potential therapeutic targets for this potentially fatal disease. Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

27 October 2021
Verified
Dataset
Closed access
CCChristopher Chen
Christopher Chen
ADAllison Drain
Allison Drain
In this clever proof-of-concept preclinical study, the authors take advantage of the regenerative Wnt-boosting activity of R-spondins and target it to liver for the treatment of liver disease. R-spondins signal in many tissues, and specificity is critical for delivery as a therapeutic for liver disease. They engineered liver specificity into R-spondin in two ways. First, they modify the R-spondins to a peptide containing only the ZNRF/RNF binding domain through truncation and mutation of the LGR-binding motif. Second, they fused this protein to a liver-specific scFv or antibody. In vivo injections of liver-targeting peptide into mice revealed proliferation and upregulation of Wnt signaling comparable to wildtype R-spondin exclusively in liver whereas the peptide fused to a nontargeting antibody showed no activity. Full length R-spondin2 stimulated Wnt signaling in both liver and small intestine. The liver-targeting peptide may also expedite resolution of liver fibrosis in a chemically induced murine cirrhosis model; however, the extent to which this formulation can heal fibrosis isn’t fully tested. This report is an interesting demonstration of a strategy to target therapeutic peptides to liver that seems likely to be generalizable to other tissues and worthy of further investigation.